雷普里根 RGEN 深 沪
已收盘 04-02 16:00:00 美东时间
117.78
-0.540
-0.46%
华盛通- 最 高121.72
- 今 开114.20
- 成交量 79.73万股
- 最 低 114.20
- 昨 收 118.32
- 总市值 66.35亿
- 52周最高 175.77
- 市盈率 静 136.26
- 换手率 1.42%
- 52周最低 109.66
- 委 比 35.14%
- 总股本 5633.11万
- 历史最高 327.32
- 量 比 0.86
- 振 幅 6.36%
- 历史最低 2.90
- 每 手 1
- 风险率 17.85%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 瑞穗上调MongoDB至"跑赢大市"，目标价从290美元升至325美元；麦格理下调小鹏评级至"中性" 目标价从24美元降至19美元
今日重点评级关注：HC Wainwright & Co.：维持Perspective Therapeutics"买入"评级，目标价从12美元升至13美元；Litchfield Hills：维持Star Equity Holdings"买入"评级，目标价从21美元升至28美元
03-24 10:07
HC Wainwright & Co. Maintains Buy on Repligen, Raises Price Target to $208
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Repligen (NASDAQ:RGEN) with a Buy and raises the price target from $180 to $208.
03-23 19:08
Repligen to Present at Leerink, Barclays, and KeyBanc Healthcare Investor Conferences
Repligen to Present at Leerink, Barclays, and KeyBanc Healthcare Investor Conferences Repligen Corporation will participate in three investor conferences in March: the Leerink Global Healthcare Conference (March 8–11, Miami), the Barclays 28th Annual Global Healthcare Conference (March 10–12, Miami)
03-05 20:31
Repligen Corporation to Present at Upcoming March Conferences
Repligen Corporation will participate in three investor conferences in March 2026: 1) Leerink Global Healthcare Conference (Miami, Mar 8-11), with CFO Jason Garland in a discussion on Mar 10. 2) Barclays 28th Annual Global Healthcare Conference (Miami, Mar 10-12), CFO Jason Garland to speak on Mar 11. 3) 2026 KeyBanc Virtual Healthcare Forum (Mar 17-18), CEO Olivier Loeillot to discuss on Mar 18.
03-05 12:30
财报速睇 | 雷普里根 2025财年年度营收7.38亿美元，同比增长16.4%；归母净利润0.49亿美元，扭亏为盈
华盛资讯2月27日讯，雷普里根公布2025财年年度业绩，公司年度营收7.38亿美元，同比增长16.4%，归母净利润0.49亿美元，扭亏为盈。
02-27 06:37
美股大行评级 | 大摩将应用材料目标价升至432美元；潜在涨幅200.0%！维尔生物科技获巴克莱升目标价至30美元，维持"超配"评级
今日重点评级关注：巴克莱：维持Vir Biotechnology"超配"评级，目标价从26美元升至30美元；巴克莱：维持Iovance Biotherapeutics"超配"评级，目标价从10美元升至11美元
02-26 09:30
Barclays Maintains Overweight on Repligen, Lowers Price Target to $175
Barclays analyst Luke Sergott maintains Repligen (NASDAQ:RGEN) with a Overweight and lowers the price target from $200 to $175.
02-26 00:06
Repligen shares are trading lower after the company reported Q4 financial results and issued FY26 adjusted EPS guidance below estimates.
Repligen shares are trading lower after the company reported Q4 financial resul...
02-24 22:02
Repligen Sees FY2026 Adj EPS $1.93-$2.01 vs $2.08 Est; Sees Sales $810.000M-$840.000M vs $824.323M Est
Repligen (NASDAQ:RGEN) is looking for FY2026 Adj EPS of $1.93-$2.01 vs $2.08 analyst estimate. sees sales of $810.000 million-$840.000 million vs $824.323 million analyst estimate.
02-24 21:20
财报速睇 | 雷普里根 2025财年Q4营收1.98亿美元，同比增长17.9%；归母净利润0.13亿美元，扭亏为盈
华盛资讯2月24日讯，雷普里根公布2025财年Q4业绩，公司Q4营收1.98亿美元，同比增长17.9%，归母净利润0.13亿美元，扭亏为盈。
02-24 21:06
